Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Protalix Biotherapeutics (PLX)  
$0.26 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: American Stock Exchange
Security Type: Common
Shares Out: 45,560,000
Market Cap: 12.06(M)
Last Volume: 1,167,076 Avg Vol: 536,427
52 Week Range: $0.2646 - $0.2646
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Protalix BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system. Co.'s proprietary ProCellEx platform is being used to manufacture its marketed product, Elelyso®, for the treatment of Gaucher disease. Co. is also developing, via ProCellEx, a pipeline of products. Co.'s clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease. In addition, Co. is developing uricase, or PRX-115, for the treatment of refractory gout.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 64,516 174,516
Total Buy Value $0 $0 $90,484 $246,299
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 1 2
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 182
  Page 2 of 8  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bio-Cell Ltd 10% Owner   –       –       •   2014-09-16 4 D $0.00 $0 I/I (8,556,371) 1,509,948     -
   Bronfeld Zeev Director   –       •      –    2014-09-16 4 A $0.00 $0 D/D 1,838,109 1,838,109     -
   Bronfeld Zeev Director   –       •      –    2014-09-16 4 D $0.00 $0 I/I (8,556,371) 1,509,948     -
   Bio-Cell Ltd 10% Owner   –       –       •   2014-08-13 4 S $2.47 $10,868,000 I/I (4,400,000) 10,066,319     -
   Bronfeld Zeev Director   –       •       •   2014-08-13 4 S $2.47 $10,868,000 I/I (4,400,000) 10,066,319     -
   Akirov Alfred Director   –       •      –    2013-08-15 4 S $5.07 $11,813 I/I (2,330) 4,915,383     -
   Akirov Alfred Director   –       •      –    2013-08-14 4 S $5.05 $555,750 I/I (110,000) 4,917,713     -
   Akirov Alfred Director   –       •      –    2013-03-12 4 S $5.70 $57,000 I/I (10,000) 5,027,713     -
   Akirov Alfred Director   –       •      –    2013-03-11 4 S $5.71 $104,737 I/I (18,300) 5,037,711     -
   Akirov Alfred Director   –       •      –    2013-03-08 4 S $5.82 $99,068 I/I (16,898) 5,056,013     -
   Akirov Alfred Director   –       •      –    2013-03-07 4 S $5.71 $48,233 I/I (8,435) 5,072,911     -
   Akirov Alfred Director   –       •      –    2013-03-06 4 S $5.68 $26,737 I/I (4,700) 5,081,346     -
   Almon Einat Brill SVP, Product Development   •       –      –    2012-07-16 4 A $0.00 $0 I/I 185,000 185,000     -
   Lauterbach Sandra Leigh VP, Sales & Commercial Affairs   •       –      –    2012-07-16 4 A $0.00 $0 I/I 20,000 20,000     -
   Yossi Maimon Vice President & CFO   •       –      –    2012-07-16 4 A $0.00 $0 I/I 185,000 185,000     -
   Palash Tzvi Chief Operating Officer   •       –      –    2012-07-16 4 A $0.00 $0 I/I 102,000 102,000     -
   Shaaltiel Yoseph Executive VP, R&D   •       •      –    2012-07-16 4 A $0.00 $0 I/I 210,000 210,000     -
   Aviezer David President & CEO   •       •      –    2012-07-16 4 A $0.00 $0 I/I 418,000 418,000     -
   Aviezer David President & CEO   •       •      –    2012-05-02 4 AS $7.13 $3,208,500 I/I (450,000) 0     -
   Aviezer David President & CEO   •       •      –    2012-05-02 4 OE $0.12 $159,421 I/I 450,000 450,000     -
   Yossi Maimon VP, Chief Financial Officer   •       –      –    2012-05-02 4 AS $7.13 $898,123 I/I (125,964) 0     -
   Yossi Maimon VP, Chief Financial Officer   •       –      –    2012-05-02 4 OE $0.97 $206,337 I/I 125,964 125,964     -
   Yossi Maimon VP, Chief Financial Officer   •       –      –    2010-10-07 4 D $9.73 $75,592 I/I (7,769) 0     -
   Yossi Maimon VP, Chief Financial Officer   •       –      –    2010-10-07 4 OE $0.97 $75,591 I/I 77,769 0     -
   Yossi Maimon VP, Chief Financial Officer   •       –      –    2010-10-07 4 AS $9.67 $676,900 I/I (70,000) 0     -

  182 Records found
  1  2  3  4  5  6  7  8   
  Page 2 of 8
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed